Clinical trial
An Observational Study of Bortezomib (BTZ) Treatment on Mantle Cell Lymphoma (MCL) in China
NCT03053024 is registered in ClinicalTrials.gov with Xian-Janssen Pharmaceutical Ltd. as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- An Observational Study of Bortezomib (BTZ) Treatment on Mantle Cell Lymphoma (MCL) in China
- Lead sponsor
- Xian-Janssen Pharmaceutical Ltd.
- Phase
- Observational
- Overall status
- Completed
- Start date
- April 14, 2017
- Completion date
- September 30, 2019
- Enrollment
- 54 (actual)
- Sites
- 9
Conditions
As the registry lists them; a condition with its own page is linked.